<DOC>
	<DOC>NCT01376739</DOC>
	<brief_summary>This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Magnevist at a dose of more than 0.2 ml/kg for MR angiography of peripheral vasculature with continuous imaging from the abdomen to the lower extremities. The objective of this study is to assess safety, especially in relation to renal dysfunction, and efficacy of using Magnevist in clinical practice. A total 2,000 patients will be recruited.</brief_summary>
	<brief_title>Magnevist Post-marketing Surveillance in Japan</brief_title>
	<detailed_description />
	<criteria>Patients who received a dose of more than 0.2 mg/kg of Magnevist for MR angiography of peripheral vasculature with continuous imaging from the abdomen to the lower extremities Patients who are contraindicated based on the product label</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Magnevist</keyword>
	<keyword>MR angiography</keyword>
</DOC>